These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 226499)

  • 1. FDA IND approval for Zn-DTPA, new clinical agent for decorporation therapy of actinides.
    Lushbaugh CC; Washburn LC
    Health Phys; 1979 Mar; 36(3):472. PubMed ID: 226499
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA IND approval for Zn-DTPA, new clinical agent for decorporation therapy of actinides.
    Lushbaugh CC; Washburn LC
    J Nucl Med; 1979 Jan; 20(1):73. PubMed ID: 219167
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA IND approval for Zn-DTPA, new clinical agent for decorporation therapy of actinides.
    Lushbaugh CC; Washburn LC
    J Occup Med; 1978 Nov; 20(11):720. PubMed ID: 213545
    [No Abstract]   [Full Text] [Related]  

  • 4. Toward an optimal DTPA therapy for decorporation of actinides: time-dose relationships for plutonium in the dog. I.
    Guilmette RA; Moretti ES; Lindenbaum A
    Radiat Res; 1979 Jun; 78(3):415-28. PubMed ID: 221958
    [No Abstract]   [Full Text] [Related]  

  • 5. Should Zn-DTPA replace Ca-DTPA for decorporation of radionuclides in man.
    Health Phys; 1976 Sep; 31(3):290-1. PubMed ID: 185166
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of Zn-DTPA in removing plutonium from the human body.
    Ohlenschläger L
    Health Phys; 1976 Feb; 30(2):249-50. PubMed ID: 1245431
    [No Abstract]   [Full Text] [Related]  

  • 7. Lauriston S. Taylor Lecture: the quest for therapeutic actinide chelators.
    Durbin PW
    Health Phys; 2008 Nov; 95(5):465-92. PubMed ID: 18849679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decorporation of inhaled plutonium nitrate from hamsters using Zn-DTPA.
    Stradling GN; Stather JW; Sumner SA; Strong JC; Lennox AM; Ham SE
    Health Phys; 1984 Apr; 46(4):919-24. PubMed ID: 6706599
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of Zn-DTPA and Ca-DTPA in removing plutonium from the human body.
    Ohlenschläger L; Schieferdecker H; Schmidt-Martin W
    Health Phys; 1978 Nov; 35(5):694-9. PubMed ID: 744734
    [No Abstract]   [Full Text] [Related]  

  • 10. Estimated toxicity of Ca-DTPA to the human fetus.
    Mays CW; Taylor GN; Fisher DR
    Health Phys; 1976 Feb; 30(2):247-9. PubMed ID: 173696
    [No Abstract]   [Full Text] [Related]  

  • 11. Decorporation of 239Pu and 241Am in the rat and hamster by Zn-DTPA.
    Volf V; Seidel A
    Radiat Res; 1974 Sep; 59(3):638-44. PubMed ID: 4428011
    [No Abstract]   [Full Text] [Related]  

  • 12. Decorporation of Pu and Am from beagles with delayed daily injections of 3,4,3-LICAM(C) or Zn-DTPA.
    Mays CW; Lloyd RD; Jones CW; Bruenger FW; Taylor GN; Durbin PW; White D; Raymond KN
    Health Phys; 1986 Apr; 50(4):530-4. PubMed ID: 3754241
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of age on the efficacy of Zn-diethylenetriaminepentaacetic acid therapy for removal of Am and Pu from beagles.
    Lloyd RD; Mays CW; Jones CW; Lloyd CR; Taylor GN; Wrenn ME
    Radiat Res; 1985 Mar; 101(3):451-9. PubMed ID: 3983361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decorporation of 241Am from mouse bone using Zn-DTPA and parathyroid hormone.
    Fisher DR; Mays CW; Dockum JG
    Health Phys; 1976 Mar; 30(3):313-5. PubMed ID: 1254487
    [No Abstract]   [Full Text] [Related]  

  • 15. ENCAPSULATED 3,4,3-LI(1,2-HOPO) IN CHITOSAN NANOPARTICLES FOR DECORPORATION VIA INHALATION.
    Chen S; Ko R; Lai EPC; Wyatt H; Abergel RJ; Li C
    Radiat Prot Dosimetry; 2018 Dec; 182(1):107-111. PubMed ID: 30165556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of Zn DTPA for the decorporation of 238Pu-TBP injected into the lungs of hamsters.
    Stradling GN; Stather JW; Ham SE; Sumner SA; Cooper JR
    Health Phys; 1983 Jun; 44(6):645-9. PubMed ID: 6853187
    [No Abstract]   [Full Text] [Related]  

  • 17. Actinide Decorporation: A Review on Chelation Chemistry and Nanocarriers for Pulmonary Administration.
    Lai EPC; Li C
    Radiat Res; 2022 Oct; 198(4):430-443. PubMed ID: 35943882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decorporation from beagles of a mixture of monomeric and particulate plutonium using Ca-DTPA and Zn-DTPA: dependence upon frequency of administration.
    Lloyd RD; Boseman JJ; Taylor GN; Bruenger FW; Atherton DR; Stevens W; Mays CW
    Health Phys; 1978 Aug; 35(2):217-27. PubMed ID: 701018
    [No Abstract]   [Full Text] [Related]  

  • 19. Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach.
    Breustedt B; Blanchardon E; Berard P; Fritsch P; Giussani A; Lopez MA; Luciani A; Nosske D; Piechowski J; Schimmelpfeng J; Sérandour AL
    Radiat Prot Dosimetry; 2009 Feb; 134(1):38-48. PubMed ID: 19351653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MADOR: a new tool to calculate decrease of effective doses in human after DTPA therapy.
    Fritsch P; Grémy O; Hurtgen C; Bérard P; Grappin L; Poncy JL
    Radiat Prot Dosimetry; 2011 Mar; 144(1-4):371-5. PubMed ID: 21131659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.